Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans.
OBJECTIVE
Oxaliplatin hypersensitivity is a well-known adverse reaction but the prevalence varies and data for frequency and clinical features have not been reported for Korea. Here we evaluates the prevalence and risk factors for hypersensitivity reactions to oxaliplatin after chemotherapy.


METHODS
Clinical information on all patients treated with oxaliplatin was retrospectively reviewed in electronic medical records between August 2009 and July 2010 in Seoul National University Bundang Hospital. Patients who experienced hypersensitivity reactions to oxaliplatin were compared with those who did not.


RESULTS
A total of 393 patients received oxaliplatin, with 42 (10.7%) experiencing hypersensitivity reactions including three cases of anaphylaxis. Median cycle of the first hypersensitivity reaction was 8. Reactions correlated with lower dexamethasone doses. Other variables were not significant.


CONCLUSIONS
The prevalence of hypersensitivity reactions was 10.7%, symptoms being mostly mild and cutaneous. Lower dexamethasone doses could be a predictor for hypersensitivity reactions to oxaliplatin.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Mi-Yeong
MY
Kim
Sung-Yoon
SY
Kang
Suh-Young
SY
Lee
Min-Suk
MS
Yang
Min-Hye
MH
Kim
Woo-Jung
WJ
Song
Sae-Hoon
SH
Kim
You Jung
YJ
Kim
Keun-Wook
KW
Lee
Sang-Heon
SH
Cho
Kyung-Up
KU
Min
Jong Seok
JS
Lee
Jee Hyun
JH
Kim
Yoon-Seok
YS
Chang
D000368:Aged; D000707:Anaphylaxis / Q000139:chemically induced / Q000453:epidemiology; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003907:Dexamethasone / Q000008:administration & dosage; D003875:Drug Eruptions / Q000453:epidemiology; D004342:Drug Hypersensitivity / Q000188:drug therapy / Q000453:epidemiology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005938:Glucocorticoids / Q000008:administration & dosage; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009369:Neoplasms / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin; D015995:Prevalence; D056910:Republic of Korea / Q000453:epidemiology; D012189:Retrospective Studies; D012307:Risk Factors; D000093542:Gemcitabine
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D006634:Histamine H1 Antagonists; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D003907:Dexamethasone; D002955:Leucovorin; D005472:Fluorouracil; D006854:Hydrocortisone; D000093542:Gemcitabine